

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217

Status	RECRUITING
Phase	Phase 3
Sponsor	Axsome Therapeutics, Inc.
Enrollment	508 participants

Key Eligibility Criteria

Inclusion (4)

- Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT
- Excessive daytime sleepiness symptoms
- Able to comply with study procedures
- Male or female, aged 18 to 65 years inclusive

Exclusion (3)

- Any clinically significant medical (e.g., OSA, narcolepsy), behavioral, or psychiatric disorder, other than MDD with EDS symptoms
- Unable to comply with study procedures
- Medically inappropriate for study participation in the opinion of the investigator

Locations (13 total)

Clinical Research Site, Chino, California, United States
Clinical Research Site, Redlands, California, United States
Clinical Research Site, Walnut Creek, California, United States
... and 10 more locations